You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deal joins Indivumed's collection of tissue biospecimens and immunohistochemistry expertise with Ultivue's multiplex immunofluorescence platform.
The drug discovery and preclinical oncology services provider attributed the revenue decline to the impact of the SARS-CoV-2 pandemic on its customers.
In its first complete quarter as a publicly traded company, Berkeley Lights reported $18.2 million in total revenues, including $4.1 million in service revenues.
The deal allows PerkinElmer to expand its portfolio of automated life sciences discovery and applied genomics products to include gene editing and gene modulation tools.
Antibacterial and psychiatric drugs could counteract gene expression patterns seen in COVID-19, according to data presented at the virtual ASHG conference.
SomaLogic and the FDA will use the company's SomaScan proteomics platform to identify circulating pharmacodynamic biomarkers for biologics.
The Broad Institute's CRISPR paralog screening platform will inform Ideaya's synthetic lethality-based target and biomarker discoveries.
The findings demonstrate the value of multi-cohort platform trials as an option for refractory cancer patients with particularly rare genomic tumor alterations.
PanCAN has partnered with Tempus to provide panel genomic testing for every patient enrolled in the Precision Promise platform study.
The newly public company has attracted attention from both investors and competitors for its technology platform used in antibody discovery workflows.
Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.
The firms aim to combine their respective products and expertise to provide comprehensive R&D solutions for drug development in oncology.
Hexagon's discovery platform is designed to identify potentially therapeutic secondary metabolites and their protein targets from fungal genomes.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
Maple Grove, Minnesota-based Stemonix will merge in an all-equity transaction with a newly formed subsidiary of Cancer Genetics, which expects to remain listed on the Nasdaq.
The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease.
The South San Francisco-based firm will use the funding to scale its Tapestri single-cell multi-omics technology to pharma trials and for characterization for cell and gene therapies.
Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.
Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.
According to Agence France Presse, astronauts who are to arrive soon at the International Space Station are to study the effect of microgravity on brain organoids.
A new study finds that farmed fish have led to a decline in genetic diversity among Atlantic salmon, the Guardian reports.
In Cell this week: analysis of SARS-CoV-2 B.1.1.7 introductions to the US, increased horizontal gene transfer higher in gut microbiomes linked to industrialization, and more.
Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.